Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Deborah Collyar: What's In It for Patients?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Jul
21
Today In Oncology
Integrating Environmental Health Into Pediatric Cancer Care May Improve Outcomes
Long-Term Outcomes With SABR in Primary Kidney Cancer
Long-Term Follow-up of Postoperative Chemoradiotherapy With Weekly vs Every-3-Week Cisplatin in Head and Neck Cancer
EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma
Mutant KRAS Vaccine for Prevention of Pancreatic Cancer Development Shows Durable Immune Responses
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo